Silence Therapeutics (SLN) Total Current Liabilities (2018 - 2026)

Silence Therapeutics' Total Current Liabilities history runs 9 years deep, the most recent figure standing at $10.5 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 45.7% year-over-year to $10.5 million; the TTM figure through Mar 2026 stood at $10.5 million (down 45.7% YoY), while the FY2025 annual figure was $13.6 million, down 19.08% from the prior year.
• Total Current Liabilities came in at $10.5 million for Q1 2026 at Silence Therapeutics, down from $13.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $25.7 million in Q4 2022 to a low of -$30.6 million in Q3 2022.
• A 5-year average of -$6.6 million and a median of -$21.1 million in 2022 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities slumped 185.69% in 2023 and surged 207.13% in 2025, its largest moves.
• Silence Therapeutics' Total Current Liabilities stood at $25.7 million in 2022, then plunged by 185.69% to -$22.1 million in 2023, then soared by 176.28% to $16.8 million in 2024, then decreased by 19.08% to $13.6 million in 2025, then declined by 23.16% to $10.5 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $10.5 million, $13.6 million, and $17.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison